6ER-009 Comparative efficacy of abemaciclib and palbociclib as adjuvant treatment in patients with early breast cancer

Abstract

Information sources: electronic prescription and computerised medical record. Statistical analysis with R ® software. Results 66 patients were included (50% women), median age 48 (IQR 38-56). Median BMI 26.3 (IQR 26-39.1). Most frequent diseases: rheumatoid arthritis (18), Crohn's disease (10), ankylosing spondylitis (8) and multiple sclerosis (7). 42% of patients had no previous comorbidity, 28% had arterial hypertension, 13.6% hypercholesterolemia and 6% depression. The median diagnosis year of the disease was 2012 (IQR 2002-2016). 37.8% of patients have had two lines of treatment, 24.2% three lines, 4.5% four lines. The most frequent drugs were anti-TNF therapy (19 adalimumab, 4 certolizumab, 4 etanercept), tocilizumab (5) secukinumab (4) and tofacitinib (4). Median scale VAS was 4 (IQR 1-6), CIS 83 (IQR 76-91) and FACIT-F 16 (11-24). Median of the PREDIMED questionnaire was 7 (low dietary adherence). No statistically significant differences were found between adherence to the Mediterranean diet and scores on quality of life questionnaires. Statistically significant differences were found with calprotectin levels and glomerular sedimentation volume. 78.7% of patients are not aware of foods with potential anti-inflammatory properties and 87.8% would like to receive dietary recommendations from healthcare professionals. Conclusion and Relevance Although more studies are needed to link diet to autoimmune diseases, it is true that an appropriate diet reduces the risk of multiple pathologies. Patients demand information and as health professionals we must give it to them and reinforce adherence to good dietary patterns such as the Mediterranean diet.